Key result
TRIM21 deficiency attenuates experimental autoimmune myocarditis progression by curbing IL-17A-driven inflammation and fibrosis.
Why the study?
The mechanisms driving progression from acute myocarditis to inflammatory dilated cardiomyopathy, and the intracellular regulators sustaining IL-17A-mediated inflammation, remain poorly understood.
TRIM21 acts as a crucial amplifier of IL-17A-driven inflammation in cardiac fibroblasts by promoting TRAF3 degradation, presenting a potential therapeutic target to prevent the progression from acute myocarditis to inflammatory dilated cardiomyopathy.
TRIM21 inhibition may attenuate autoimmune myocarditis in models; leaves open translation to human inflammatory cardiomyopathy.
Myocarditis is a potentially fatal disease that can progress to inflammatory dilated cardiomyopathy (DCMi), a condition that is a leading cause of noncongenital heart failure in young adults. However, the mechanisms driving the transition from acute myocarditis to DCMi remain poorly understood. Although IL-17A-mediated inflammation is a well-known driver of this progression, the intracellular regulators that sustain and amplify this response remain unclear. Here, we identify the E3 ubiquitin ligase TRIM21, which is upregulated in the hearts of DCMi patients and experimental autoimmune myocarditis (EAM) mice, as a key amplifier of IL-17A-driven inflammation in cardiac fibroblasts (CFs), promoting disease progression and fibrosis. TRIM21 deficiency significantly attenuates EAM progression, reducing inflammatory cell infiltration and fibrotic remodeling. Mechanistically, TRIM21 is induced by IL-17A in CFs and promotes K27-linked polyubiquitination and lysosomal degradation of TRAF3, a negative regulator of IL-17A signaling, thereby establishing a self-reinforcing IL-17A-TRIM21–TRAF3 positive feedback loop. Finally, specific knockdown of TRIM21 in CFs via the AAV9-Postn strategy effectively alleviates EAM severity. These findings identify TRIM21 as an intracellular mediator of sustained IL-17A signaling in myocarditis and highlight its potential as a therapeutic target for preventing progression to DCMi.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied Autoimmune myocarditis and inflammatory dilated cardiomyopathy. TRIM21 deficiency or cardiac fibroblast-specific TRIM21 knockdown (AAV9-Postn-Trim21-RNAi) vs. Wild-type mice or AAV9-Postn-NC-RNAi was evaluated on Myocardial inflammation, fibrotic remodeling, and cardiac function in experimental autoimmune myocarditis. TRIM21 deficiency or fibroblast-specific knockdown significantly attenuated experimental autoimmune myocarditis progression by reducing IL-17A-driven inflammation and fibrotic remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: